Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

PCOT for Outpatients With Acute Respiratory Tract Infection at Risk of Severe Disease in Primary Healthcare

NCT07159230 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2025-09-15
Last updated
2025-09-08

Condition(s) studied

Acute Respiratory Tract Infection

Investigational drug(s) / intervention(s)

point-of-care multiplex PCR test

point-of-care multiplex PCR test: community health care center in intervention group were provided with point-of-care multiplex PCR test (POCT) plus routine test. POCT testing was recommended for all enrolled patients presenting with acute respiratory infections who meet the predefined inclusion criteria. The therapeutic interventions were determined by health-care workers on the basis of POCT result, clinical assessment and guideline.

Study summary

This study aims to evaluate the clinical value of point-of-care multiplex PCR testing (POCT) in guiding early diagnosis and target treatment for acute respiratory infections in primary healthcare settings.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Onset time\<=7 days; 2. First visit; 3. Age\>=18 years old; 4. Patients with acute upper respiratory tract infection with severe high-risk factors, or patients with acute lower respiratory tract infection; 5. The condition is allowed to be treated in an outpatient clinic; 6. Signed informed consent. Exclusion Criteria: 1. The doctor judges that the disease is serious and requires hospitalization; 2. New unclear consciousness; 3. Respiratory rate\>=30 beats/min; 4. Hypoxemia or respiratory failure; 5. Heart rate\> 125 beats/min; 6. Systolic blood pressure \< 90 or diastolic blood pressure \< 60 mmHg; 7. Known active tuberculosis; 8. Pregnant and lactating women; 9. Have participated in this study within 90 days;

Primary outcome measure(s)

  • The incidence rates of respiratory failure and hospitalization — within 14 days after the diagnosis of acute respiratory infection

Trial sites (1)

FacilityCityRegionStatus
Xincheng District Hospital, Hohhot; Genghis Khan Community Health Service Center; East Street & West Street Sub-district Community Health Service Center; East Yingxin Road Community Health Service Center and so on Hohhot Inner Mongolia
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07159230 on ClinicalTrials.gov ↗ ← All trials in China